Astrocyte dysfunction in epileptogenesis: the role of adenosine Project Summary/Abstract This grant proposal studies the hypothesis that astrogliosis and resulting dysfunction of adenosine-based neuromodulation is a mechanistic cause for the development of epilepsy (i.e. epileptogenesis). This is of importance, since to date no effective prophylaxis for epilepsy is available. This proposal will explore status epilepticus (SE)- triggered epileptogenesis and dysfunction of the endogenous adenosine-based seizure control system in mice in search for an astrocyte-based mechanism of epileptogenesis and thus may provide a foundation for the development of novel antiepileptogenic therapies. The proposal is based on the following findings: (i) Adenosine kinase (ADK) is the key enzyme for the regulation of adenosine;(ii) In adult brain, ADK is expressed in astrocytes;(iii) Astrogliosis is a hallmark of epileptogenesis;(iv) ADK is over-expressed within epileptic astrogliotic hippocampus;(v) Augmentation of adenosine by implants of adenosine releasing cells prevents kindled seizures. (vi) Transgenic overexpression of ADK increases seizure susceptibility;(vii) Local reduction of ADK in transgenic mice prevents epileptogenesis. Our CENTRAL HYPOTHESIS is that an epileptogenesis triggering event (e.g. SE) induces astrogliosis with resultant regional upregulation of ADK as a necessary component of epileptogenesis and that reconstitution of brain adenosine by stem cell derived brain implants can prevent such epileptogenesis. The model system to address this hypothesis consists of intraamygdaloid application of kainic acid (KA) to initiate epileptogenesis selectively in the CA3 area of the hippocampal formation of mice and to transplant ADK-deficient adenosine releasing embryonic stem (ES) cells into the epileptogenic region.
SPECIFIC AIMS :
In Aim 1 we will study the causal, temporal, and spatial relations of astrogliosis, upregulation of ADK and seizures in a mouse model of CA3-selective epileptogenesis.
In Aim 2 we will use a panel of different Adk-transgenic mice, in which we can molecularly separate cell-type specific functions of ADK expression from astrogliosis, to study both mechanisms independently.
In Aim 3 we will use ADK-deficient ES cell-derived intrahippocampal implants in a therapeutic approach to prevent epileptogenesis. The expected outcome of these studies is to define astrocytic ADK as a target for the prevention of epileptic seizures and to translate these findings into a novel stem cell based treatment approach.
Currently, no therapy is available to prevent the development of epilepsy. This proposal studies a defective function of the brain's own adenosine-based seizure control system as a mechanistic cause for epilepsy and translates these findings into a novel approach to prevent epilepsy by implanting adenosine releasing stem cells.
|Richerson, George B; Boison, Detlev; Faingold, Carl L et al. (2016) From unwitnessed fatality to witnessed rescue: Pharmacologic intervention in sudden unexpected death in epilepsy. Epilepsia 57 Suppl 1:35-45|
|Diogenes, Maria Jose; Neves-Tome, Raquel; Fucile, Sergio et al. (2014) Homeostatic control of synaptic activity by endogenous adenosine is mediated by adenosine kinase. Cereb Cortex 24:67-80|
|Shen, Hai-Ying; Sun, Hai; Hanthorn, Marissa M et al. (2014) Overexpression of adenosine kinase in cortical astrocytes and focal neocortical epilepsy in mice. J Neurosurg 120:628-38|
|Flaten, Vanessa; Laurent, Cyril; Coelho, Joana E et al. (2014) From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease? Biochem Soc Trans 42:587-92|
|Kawamura Jr, Masahito; Ruskin, David N; Geiger, Jonathan D et al. (2014) Ketogenic diet sensitizes glucose control of hippocampal excitability. J Lipid Res 55:2254-60|
|Ruskin, David N; Svedova, Julia; Cote, Jessica L et al. (2013) Ketogenic diet improves core symptoms of autism in BTBR mice. PLoS One 8:e65021|
|Williams-Karnesky, Rebecca L; Sandau, Ursula S; Lusardi, Theresa A et al. (2013) Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis. J Clin Invest 123:3552-63|
|Boison, Detlev (2013) Adenosine kinase: exploitation for therapeutic gain. Pharmacol Rev 65:906-43|
|Wu, M; Sahbaie, P; Zheng, M et al. (2013) Opiate-induced changes in brain adenosine levels and narcotic drug responses. Neuroscience 228:235-42|
|Aronica, Eleonora; Sandau, Ursula S; Iyer, Anand et al. (2013) Glial adenosine kinase--a neuropathological marker of the epileptic brain. Neurochem Int 63:688-95|
Showing the most recent 10 out of 36 publications